Health Care • Biotechnology: Pharmaceutical Preparations
$30.53 ▼ -0.41
(-1.32%)
MKT CAP: $2.20B • VOL: 1.11M
52W L $23 52W H $56
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
VERA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$315.5M | -$167.2M | -$102.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$299.6M | -$152.1M | -$96.0M |
| EBITDA (Normalized) | -$315.0M | -$166.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$241.1M | -$134.7M | -$92.2M |
| Capital Expenditures (CapEx) | $630.0K | $972.0K | — |
| Free Cash Flow (FCF) | -$241.7M | -$135.7M | -$92.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -27.3% | — |
| Cash & Short-Term Equivalents | $354.7M | $92.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $604.5M | $577.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VERA.